<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459771</url>
  </required_header>
  <id_info>
    <org_study_id>M06HER</org_study_id>
    <secondary_id>2006-001707-11</secondary_id>
    <nct_id>NCT00459771</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity</brief_title>
  <official_title>Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan vs placebo in
      prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer
      treated with trastuzumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized pharmacological intervention study

      Primary objectives:

      - to determine whether concurrent ATII-antagonist treatment can prevent trastuzumab-related
      cardiotoxicity, defined as a decline in LVEF of more than 15% or a decrease to an absolute
      value &lt;45%

      Secondary objectives:

        -  To determine if 'Brain Natriuretic Peptide' (NT-proBNP) and troponin T can be used as
           surrogate marker in the monitoring of trastuzumab-associated cardiotoxicity

        -  To determine genetic variability in relevant genes such as the HER2 gene (by assessing
           single nucleotide polymorphisms [SNPs] in the kinase domain) and explore any
           correlations with trastuzumab induced cardiotoxicity 3) To determine the reversibility
           of a decrease in left ventricular ejection fraction (LVEF) associated with trastuzumab
           treatment

      Arm I : placebo Arm II : AT1 blocker candesartan (32 mg/day; run in 16 mg during week 1)

      Randomization: before chemotherapy treatment period. Study period: chemotherapy period,
      trastuzumab treatment period 26 weeks follow up after discontinuation of trastuzumab
      treatment and thereafter 1 month follow-up after end of placebo or AT1 blocker.

      Candesartan treatment will start the same day as the first infusion of trastuzumab and will
      continue up to 26 weeks after the end of treatment with trastuzumab.

      Women with primary HER2 positive breast cancer who are considered for adjuvant systemic
      treatment with anthracycline containing chemotherapy and trastuzumab.

      Before start of anthracycline treatment:

        -  Medical history, physical examination

        -  New York Heart Association (NYHA) score

        -  Cardiac questionnaire

        -  Electrocardiogram

        -  MUGA scan

        -  Laboratory assessments; hemoglobin, hematocrit, white blood cell count, platelet count,
           serum creatinine, sodium, potassium, calcium, thyroid stimulating hormone, glucose,
           cholesterol, bilirubin, alkaline phosphatase, ASAT/ALAT, LDH, albumin, NT-proBNP,
           troponin T analysis

        -  Pregnancy test

        -  Genotype analysis

      Every chemotherapy cycle

      - Laboratory assessments; hemoglobin, hematocrit, white blood cell count, platelet count,
      serum creatinine, sodium, potassium, calcium, glucose, bilirubin, alkaline phosphatase,
      ASAT/ALAT, LDH, albumin, (NT-proBNP, troponin T analysis)

      Before start of trastuzumab treatment:

        -  Physical examination

        -  New York Heart Association (NYHA) score

        -  Cardiac questionnaire

        -  Electrocardiogram

        -  MUGA scan

        -  Laboratory assessments; hemoglobin, hematocrit, white blood cell count, platelet count,
           serum creatinine, sodium, potassium, calcium, glucose, bilirubin, alkaline phosphatase,
           ASAT/ALAT, LDH, albumin, NT-proBNP, troponin T analysis

      After 3, 6 and 9 months trastuzumab:

        -  Physical examination

        -  New York Heart Association (NYHA) score

        -  Cardiac questionnaire

        -  MUGA scan

        -  Laboratory assessments; hemoglobin, hematocrit, white blood cell count, platelet count,
           serum creatinine, sodium, potassium, calcium, glucose, bilirubin, alkaline phosphatase,
           ASAT/ALAT, LDH, albumin, NT-proBNP, troponin T analysis

      After 1 year trastuzumab, 26 weeks after the last trastuzumab administration:

        -  Physical examination

        -  New York Heart Association (NYHA) score

        -  Cardiac questionnaire

        -  Electrocardiogram

        -  MUGA scan

        -  Laboratory assessments; hemoglobin, hematocrit, white blood cell count, platelet count,
           serum creatinine, sodium, potassium, calcium, glucose, bilirubin, alkaline phosphatase,
           ASAT/ALAT, LDH, albumin, NT-proBNP, troponin T analysis

      The primary endpoint of the study is the deterioration of the cardiac function defined as a
      decline in LVEF of 15% or more to an absolute value below 45% during the year with
      trastuzumab.

      From previous studies it is estimated that about 30% of the patients treated with trastuzumab
      will show deterioration of LVEF.

      A total of 200 patients will receive trastuzumab and candesartan or trastuzumab and placebo
      in this double blind placebo-controlled study. The number of patients randomized (= before
      chemotherapy period) for this trial shall be more than 200 as a small number of patients
      might drop out before start of therapy with trastuzumab. This number cannot exactly be
      determined beforehand.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of cardiotoxicity, defined as a decline in LVEF (MUGA) of more than 15% or a decrease of less than 15% to an absolute value below 45%.</measure>
    <time_frame>during 1 year trastuzumab therapy and during 26 weeks after discontinuation of trastuzumab</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candasartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT1 blocker candesartan</intervention_name>
    <description>AT1 blocker candesartan, 32 mg oral QD</description>
    <arm_group_label>Candesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 32 mg, oral QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged ≥18 years

          -  WHO: ≤ 2

          -  Strongly HER2-positive breast cancer, defined as an immunohistochemistry score of 3+
             using the HercepTestTM, or gene amplification by fluorescence in situ hybridization,
             or chromogenic in situ hybridization (CISH).

          -  Serum creatinine &lt;140 umol/l or creatinine clearance &gt; 50 ml/min (by Cockcroft-Gault
             formula)

          -  Thyroid stimulating hormone between 0.5-3.9 MU/l

          -  Blood pressure systolic ≥ 140 mmHg and diastolic ≥ 90 mmHg is acceptable at
             randomization. However prior to the first administration of trastuzumab blood pressure
             should be regulated and should be systolic ≥ 100 mmHg and ≤ 180 mmHg and diastolic ≥
             60 mmHg and ≤ 100 mmHg. (blood pressure should be regulated according to the
             guidelines of appendix 5)

          -  LVEF ³ 50% assessed by multigated angiography (MUGA) or cardiac ultrasound

          -  Adjuvant regimen: trastuzumab start ≥ 3 weeks after day 1 of the last anthracycline
             chemotherapy cycle

          -  Trastuzumab treatment according to standard medical care

          -  Written informed consent to participate in the study

        Exclusion Criteria:

          -  Prior anthracycline chemotherapy regimen or anti-HER2 therapy, or other prior biologic
             or immunotherapy for breast cancer treatment or any malignancy

          -  Previous malignancy requiring chemotherapy or radiotherapy

          -  Uncontrolled serious concurrent illness

          -  Patients with New York Heart Association (NYHA) class II/III/IV congestive heart
             failure

          -  Myocardial infarction &lt; 6 months before randomization

          -  Treatment with ACE inhibitor, ATII blocker, or lithium. Patients treated with ACE
             inhibitor, or ATII blocker can switch (after randomization and during the chemotherapy
             period) to alternative antihypertensive therapy; see appendix 5.

          -  History of hypersensitivity to the study medication

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.H.M. Schellens, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis de Tjongerschans</name>
      <address>
        <city>Heerenveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum voor Noord-Limburg</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Streekziekenhuis Koningin Beatrix</name>
      <address>
        <city>Winterswijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2007</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>angiotensin II-receptor (AT1) blocker</keyword>
  <keyword>prevention</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>cardiotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

